Ann-Marie E Bröske

1.9k total citations
14 papers, 747 citations indexed

About

Ann-Marie E Bröske is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Ann-Marie E Bröske has authored 14 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Molecular Biology. Recurrent topics in Ann-Marie E Bröske's work include Monoclonal and Polyclonal Antibodies Research (7 papers), CAR-T cell therapy research (5 papers) and Peptidase Inhibition and Analysis (3 papers). Ann-Marie E Bröske is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), CAR-T cell therapy research (5 papers) and Peptidase Inhibition and Analysis (3 papers). Ann-Marie E Bröske collaborates with scholars based in Switzerland, Germany and United Kingdom. Ann-Marie E Bröske's co-authors include Elena Mancini, Achim Leutz, Sten Eirik W. Jacobsen, Andreas Enns, Claus Nerlov, Frank Rosenbauer, Matthew R. Huska, Rudolf Jaenisch, Marina Scheller and Marco Prinz and has published in prestigious journals such as Nature Genetics, Blood and Frontiers in Immunology.

In The Last Decade

Ann-Marie E Bröske

14 papers receiving 737 citations

Peers

Countries citing papers authored by Ann-Marie E Bröske

Since Specialization

Citations

This map shows the geographic impact of Ann-Marie E Bröske's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann-Marie E Bröske with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann-Marie E Bröske more than expected).

Fields of papers citing papers by Ann-Marie E Bröske

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann-Marie E Bröske. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann-Marie E Bröske. The network helps show where Ann-Marie E Bröske may publish in the future.

Co-authorship network of co-authors of Ann-Marie E Bröske

This figure shows the co-authorship network connecting the top 25 collaborators of Ann-Marie E Bröske. A scholar is included among the top collaborators of Ann-Marie E Bröske based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann-Marie E Bröske. Ann-Marie E Bröske is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Investigating the complex interplay between fibroblast activation protein α-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy 2024 ·Frontiers in Immunology ·Anton Kraxner, (unknown), Wei‐Yi Cheng, Tai-Hsien Ou Yang, (unknown), Marta Cañamero, Emilia Andersson, (unknown), Sebastian Dziadek, Ann-Marie E Bröske, Maurizio Ceppi, Tamara Tanos, Volker Teichgräber, Jehad Charo	8
2	Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies 2024 ·Frontiers in Immunology ·Sebastian Dziadek, Anton Kraxner, Wei‐Yi Cheng, Tai-Hsien Ou Yang, (unknown), Noah Theiss, Tsu‐Shuen Tsao, Emilia Andersson, (unknown), Ann-Marie E Bröske, Maurizio Ceppi, Volker Teichgräber, Jehad Charo	15
3	Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody 2023 ·Blood ·Iryna Dekhtiarenko, (unknown), Wolfgang Jacob, (unknown), Maja Weisser, Carmelo Carlo‐Stella, Salomon Manier, Simon J. Harrison, Rakesh Popat, (unknown), Ann-Marie E Bröske	8
4	P-006 SBCMA has utility for early response monitoring in the blood and is correlated with forimtamig pharmacodynamic activity, clinical response and MRD 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Iryna Dekhtiarenko, (unknown), (unknown), (unknown), (unknown), Wolfgang Jacob, (unknown), Maja Weisser, Carmelo Carlo‐Stella, Salomon Manier, Simon J. Harrison, Rakesh Popat, Caroline Hasselbalch Riley, Ann-Marie E Bröske	1
5	Molecular Mechanisms Underlying Response and Resistance to Glofitamab 2023 ·Blood ·Sina Nassiri, Stephan Schmeing, (unknown), Sylvia Herter, Llucia Albertí Servera, Tamara Hüsser, Emilio Yángüez, Diana Dunshee, Koorosh Korfi, Pablo Umaña, Ann-Marie E Bröske, Alessia Bottos, Marina Bacac	2
6	Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma 2021 ·Blood Advances ·Ann-Marie E Bröske, Koorosh Korfi, Anton Belousov, (unknown), Chia-Huey Ooi, Christopher R. Bolen, Marta Cañamero, Enrique Gómez Alcaide, Ian James, Emily Piccione, David Carlile, Natalie Dimier, Pablo Umaña, Marina Bacac, Maja Weisser, Michael Dickinson	46
7	PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor 2020 ·Clinical Pharmacology & Therapeutics ·Kevin Smart, Ann-Marie E Bröske, Dominik Rüttinger, (unknown), Alex Phipps, Antje‐Christine Walz, Carola H. Ries, Monika Baehner, Michael A. Cannarile, Georgina Meneses‐Lorente	13
8	Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 2019 ·Blood ·Nassim Djebli, (unknown), (unknown), François Mercier, Nicole A. Kratochwil, Ann-Marie E Bröske, Natalie Dimier, Cristiano Ferlini, Tom Moore, Maja Weisser, Peter N. Morcos	7
9	Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial 2019 ·Blood ·Franck Morschhauser, Carmelo Carlo‐Stella, Fritz Offner, Gilles Salles, Martin Hutchings, Gloria Iacoboni, Anna Sureda, Michael Crump, Joaquín Martínez‐López, (unknown), Peter N. Morcos, Cristiano Ferlini, K. Abiraj, Ann-Marie E Bröske, Marina Bacac, Natalie Dimier, Tom Moore, Maja Weisser, Michael Dickinson	24
10	CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial 2019 ·Blood ·Ann-Marie E Bröske, Ian James, Anton Belousov, Enrique Gómez Alcaide, Marta Cañamero, Chia-Huey Ooi, Nils Grabole, (unknown), Koorosh Korfi, Nicole A. Kratochwil, Peter N. Morcos, Cristiano Ferlini, (unknown), Natalie Dimier, Tom Moore, Marina Bacac, Maja Weisser, Michael Dickinson	5
11	CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 2019 ·Blood ·Martin Hutchings, Giuseppe Gritti, Anna Sureda, María José Terol, Martin J.S. Dyer, Gloria Iacoboni, William Townsend, Marina Bacac, Ann-Marie E Bröske, Natalie Dimier, Cristiano Ferlini, K. Abiraj, Angelika Lahr, Katharina Lechner, Tom Moore, Peter N. Morcos, Anesh Panchal, Maja Weisser, (unknown)	20
12	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia 2016 ·Oncotarget ·Norbert Vey, Jacques Delaunay, Giovanni Martinelli, Walter Fiedler, Emmanuel Raffoux, Thomas Prébet, Carlos Gomez‐Roca, Cristina Papayannidis, Maxim Kebenko, Peter Paschka, R D Christen, Ernesto Guarin, Ann-Marie E Bröske, Monika Baehner, Michael Brewster, Antje‐Christine Walz, Francesca Michielin, Valeria Runza, Valérie Méresse, Christian Récher	73
13	Mesenchymal Stromal Cell Characteristics Vary Depending on Their Origin 2013 ·Stem Cells and Development ·Heike Wegmeyer, Ann-Marie E Bröske, Mathias Leddin, (unknown), (unknown), Julia Hupfeld, (unknown), (unknown), (unknown), (unknown), S. Knothe, Jürgen Funk, Ralf Huss, Markus Neubauer	176
14	DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction 2009 ·Nature Genetics ·Ann-Marie E Bröske, (unknown), Shabnam Kharazi, Matthew R. Huska, Elena Mancini, Marina Scheller, (unknown), Andreas Enns, Marco Prinz, Rudolf Jaenisch, Claus Nerlov, Achim Leutz, Miguel A. Andrade‐Navarro, Sten Eirik W. Jacobsen, Frank Rosenbauer	349

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact